Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Quote Panel
Key Metrics
Fundamentals
Relative Strength
BMKDF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Forecast
Analyst rating
Last analyst upgrade/downgrade
Earnings Growth
YoY
Current
Estimates
Q1.23
N/A
NA
vs NA
Q2.23
N/A
NA
vs NA
Q3.23
N/A
NA
vs NA
Q4.23
N/A
NA
vs NA
Q1.24
N/A
NA
vs NA
Q2.24
N/A
NA
vs NA
Q3.24
N/A
NA
vs NA
Q4.24
N/A
NA
vs NA
Q1.25
N/A
NA
vs NA
Q2.25
N/A
NA
vs NA
Sales Growth
YoY
Current
Estimates
Q1.23
+65%
39.7K vs 24.1K
Q2.23
+11%
39.7K vs 35.9K
Q3.23
+3%
42.1K vs 41K
Q4.23
+13%
41.5K vs 36.9K
Q1.24
+0%
39.8K vs 39.7K
Q2.24
-4%
38.3K vs 39.7K
Q3.24
-9%
38.3K vs 42.1K
Q4.24
-7%
38.6K vs 41.5K
Q1.25
-2%
39K vs 39.8K
Q2.25
+2%
39K vs 38.3K
Return on Equity
QoQ
Q1.23
+44%
0.44
vs 0.45
Q2.23
+37%
0.37
vs 0.44
Q3.23
+18%
0.18
vs 0.37
Q4.23
+73%
0.73
vs 0.18
Q1.24
+64%
0.64
vs 0.73
Q2.24
+96%
0.96
vs 0.64
Q3.24
+53%
0.53
vs 0.96
Q4.24
+30%
0.3
vs 0.53
Q1.25
-24%
-0.24
vs 0.3
Q2.25
-31%
-0.31
vs -0.24
Institutionnal Ownership
N/A
Q2.23
NA
NA
vs NA
NA
Q3.23
NA
NA
vs NA
NA
Q4.23
NA
NA
vs NA
NA
Q1.24
NA
NA
vs NA
NA
Q2.24
NA
NA
vs NA
NA
Q3.24
NA
NA
vs NA
NA
Q4.24
NA
NA
vs NA
NA
Q1.25
NA
NA
vs NA
NA
Q2.25
NA
NA
vs NA
NA
Q3.25
NA
NA
vs NA
NA
newsfilecorp.com
8 hours ago
proactiveinvestors.com
9 hours ago
BioMark Diagnostics Inc., an oncology focused company, develops cancer diagnostic solutions to detect, monitor, and assess early treatment. It has a collaborative research agreement with the Icahn School of Medicine for clinical studies related to early lung cancer diagnosis. The company was incorporated in 2014 and is headquartered in Richmond, Canada. BioMark Diagnostics Inc. is a subsidiary of Biomark Technologies Inc.
OTC
0.00Â ( 0.40%)
Relative Strenght
Volume Buzz
-84%
Earning Acce
No
Dist 52w H.
5%Relative Strength
BMKDF
Sector
Top 5 RS in Group
Symbol | Company | RS | 5-Day Perf. |
|---|---|---|---|
Quote Panel
Key Metrics
Fundamentals
P/E Ratio
P/S Ratio
P/B Ratio
Debt/Equity
Net Margin
EPS
How BMKDF compares to sector?
Forecast
2025-Revenue
2025-EPS
2025-EBITDA
Analyst rating
Strong Sell
Sell
Buy
Neutral
Strong Buy
Price Target
N/A(N/A)
Number of analyst
N/A
Last analyst upgrade/downgrade
No Data Available